



## Director/PDMR Shareholding

August 13, 2021

RNS Number : 63111

Renalytix PLC

13 August 2021

**Renalytix plc**  
("Renalytix" or the "Company")

### Director/PDMR Dealing

**New York, 13 August 2021** - Renalytix (LSE: RENX) announces that it has been advised of the sale by O. James Sterling, the Company's Chief Financial Officer, of 12,000 American Depositary Shares ("ADS"), each representing two ordinary shares of £0.0025 each in the capital of the Company ("**Ordinary Shares**"), under a Rule 10b5-1 trading plan established in accordance with Rule 10b5-1 under the U.S. Securities Exchange Act of 1934, as amended, and the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018 ("**MAR**").

Rule 10b5-1 plans permit directors, officers and other company insiders to adopt, at times when they are not in possession of material, non-public information, or inside information, written plans for trading securities in a non-discretionary, pre-scheduled manner in the future.

Following completion of the sale, O. James Sterling is interested in 1,811,236 Ordinary Shares representing 2.51% of the current issued share capital of the Company.

#### ***For further information, please contact:***

**Renalytix plc**  
James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)  
**Via Walbrook PR**

**Stifel (Nominated Adviser, Joint Broker)**  
Alex Price / Nicholas Moore

**Tel: 020 7710 7600**

**Investec Bank plc (Joint Broker)**  
Gary Clarence / Daniel Adams

**Tel: 020 7597 4000**

**Walbrook PR Limited**  
Paul McManus / Lianne Cawthorne

**Tel: 020 7933 8780** or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)  
Mob: 07980 541 893 / 07584 391 303

#### **About Kidney Disease**

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD). Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not

know they have CKD\*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year kidney disease kills more people than breast and prostate cancer. Every day, 13 patients in the United States die while waiting for a kidney transplant.

\* <https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html>

#### About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical *in vitro* diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit [www.renalytixai.com](http://www.renalytixai.com)

The information contained in this notification is disclosed in accordance with the requirements of MAR.

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name	O. James Sterling	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	Chief Financial Officer	
b)	Initial notification /Amendment	Initial Notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Renalytix plc	
b)	Legal Entity Identifier	213800NTOH3FK3WER551	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument	ADS', each ADS representing two Ordinary Shares of £0.0025 each.	
	Identification code	US75973T1016	
b)	Nature of the transaction	Sale of ADS' under a 10b5-1 trading plan	
c)	Currency	US Dollar	
d)	Price(s) and volume(s)	Price(s)	Volume(s)

		\$28.15	6000 ADS (representing 12000 Ordinary Shares)
e)	Aggregated information - Aggregated volume - Price - Aggregated total	6000 ADS (representing 12000 Ordinary Shares) \$28.15 \$168,900	
f)	Date of the transaction	10 August 2021	
g)	Place of the transaction	Nasdaq Stock Exchange	

<b>1</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name	O. James Sterling	
<b>2</b>	<b>Reason for the notification</b>		
a)	Position/status	Chief Financial Officer	
b)	Initial notification /Amendment	Initial Notification	
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Renalytix plc	
b)	Legal Entity Identifier	213800NTOH3FK3WER551	
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>		
a)	Description of the financial instrument, type of instrument  Identification code	ADS', each ADS representing two Ordinary Shares of £0.0025 each.  US75973T1016	
b)	Nature of the transaction	Sale of ADS' under a 10b5-1 trading plan	
c)	Currency	US Dollar	

d)	Price(s) and volume(s)	Price(s)	Volume(s)
		\$28.00	6000 ADS (representing 12000 Ordinary Shares)
e)	Aggregated information - Aggregated volume - Price - Aggregated total	6,000 ADS (representing 12,000 Ordinary Shares) \$28 \$168,000	
f)	Date of the transaction	12 August 2021	
g)	Place of the transaction	Nasdaq Stock Exchange	

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lse.com](mailto:rns@lse.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHEAEPDFLKFEFA